Predictmedix (PMED) AI Stock Analysis

• Market Cap: C$11.37M
• Dividend Yield: N/A
• Average Volume (3M): 287.98K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.45
• Revenue Growth: N/A
• EPS Growth: 9.21%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 206,787,540
• 10 Day Avg. Volume: 97,531
• 30 Day Avg. Volume: 287,981
• PEG Ratio: 0.04
• Price to Book (P/B): -1.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -61.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.06 ▲(60.00% Upside)

The score is held down primarily by very weak financial performance (minimal revenue, persistent losses, negative free cash flow, and negative equity). Technicals are mixed but not strongly bearish, and recent corporate announcements/financings are supportive; however, valuation is constrained by ongoing losses and the lack of a dividend yield.

Predictmedix Business Overview & Revenue Model

Company Description

Predictmedix (PMED) is a technology company that operates in the healthcare sector, specializing in artificial intelligence (AI) driven solutions. The company focuses on developing AI-powered technologies designed to enhance workplace health and safety. Its core products include impairment detection systems and solutions for rapid health assessments, aiming to improve safety and efficiency across various industries.

How the Company Makes Money

Predictmedix generates revenue primarily through the sale and licensing of its AI-driven technologies. The company offers its products to businesses across sectors such as healthcare, manufacturing, and public safety. Key revenue streams include direct sales of hardware and software solutions, subscription-based services for ongoing access to their AI platforms, and partnerships with third-party vendors and service providers who integrate Predictmedix's technologies into their own offerings. Additionally, the company may engage in research and development collaborations that provide additional funding and resources.

Predictmedix Financial Statement Overview

Summary

Predictmedix exhibits significant financial challenges across all metrics, with declining revenue and profitability, weak balance sheet health due to negative equity, and poor cash flow dynamics. The company must address operational inefficiencies and improve its revenue generation to enhance financial stability.

Income Statement

The company has struggled with generating revenue and maintaining profitability. Persistent negative net income and declining total revenue, particularly with zero revenue in the latest fiscal year, reflect significant challenges. The gross and net profit margins are negative, indicating inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reflects a weak financial position with negative stockholders' equity, indicating liabilities exceed assets. The equity ratio is negative, further highlighting financial distress. However, the absence of total debt provides a slight buffer against solvency risk.

Cash Flow

The company has consistently negative operating and free cash flows, with significant cash burn. While financing cash flow is positive, indicating reliance on external funding, this is unsustainable without positive operating cash flow. The free cash flow to net income ratio is unfavorable, showing cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	35.02K	134.82K	0.00
Gross Profit	-53.55K	-155.31K	-167.63K	26.62K	84.82K	-3.51K
EBITDA	-849.06K	-788.14K	-1.82M	-1.91M	-1.80M	-1.93M
Net Income	-1.18M	-1.18M	-1.99M	-2.07M	-1.88M	-1.93M
Balance Sheet
Total Assets	485.90K	131.95K	481.33K	717.74K	1.24M	1.00M
Cash, Cash Equivalents and Short-Term Investments	313.74K	0.00	36.87K	79.25K	211.30K	480.05K
Total Debt	0.00	0.00	0.00	37.87K	0.00	15.19K
Total Liabilities	1.29M	1.45M	625.14K	871.12K	349.67K	135.35K
Stockholders Equity	-799.49K	-1.32M	-143.82K	-153.39K	886.99K	868.29K
Cash Flow
Free Cash Flow	-761.17K	-36.87K	-1.64M	-678.85K	-1.95M	-1.27M
Operating Cash Flow	-761.17K	-36.87K	-1.64M	-534.17K	-1.53M	-1.08M
Investing Cash Flow	0.00	0.00	0.00	-144.68K	-418.12K	-195.01K
Financing Cash Flow	1.07M	0.00	1.60M	546.80K	1.68M	261.12K

Predictmedix Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PMED, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.06, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.60 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PMED.

Predictmedix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	70 Outperform	C$216.62M	-14.25	-10.51%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$22.64M	-5.65	―	―	28.59%	23.46%
PMED	46 Neutral	C$11.37M	-7.25	―	―	―	9.21%
PINK	46 Neutral	C$37.22M	-1.62	-181.70%	―	209.29%	35.38%
BLO	46 Neutral	C$75.07M	-11.48	-188.03%	―	―	-52.41%

Predictmedix Corporate Events

Predictmedix to Rebrand as QScreen AI, Betting on Quantum-Inspired Healthcare AI

Predictmedix AI Inc. plans to rebrand as QScreen AI Inc., with a new ticker symbol QAI, marking a strategic shift to position itself as a leading healthcare innovator at the intersection of artificial intelligence, quantum-inspired computing and data-driven health solutions, subject to regulatory approval. Leveraging more than 720,000 real-world health scans from its SmartHealth AI Stations, the company aims to use quantum-inspired algorithms to enhance preventive screening, diagnostics and personalized care with higher accuracy and inclusivity on standard hardware, while onboarding strategic industry experts to drive global commercialization and strengthen its competitive position in the emerging quantum-AI healthcare market.

The most recent analyst rating on (TSE:PMED) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on Predictmedix stock, see the TSE:PMED Stock Forecast page.

Predictmedix AI Closes 2025 with Quantum AI Advancements and Strong Growth

Predictmedix AI Inc. marked significant advancements in 2025, enhancing its AI-driven health screening technology and integrating quantum-inspired computation to improve accuracy and scalability. The company achieved over 500,000 real-world scans with its SmartHealth AI Stations, expanded global investor engagements, and demonstrated the resilience and effectiveness of its multi-vertical growth strategy. Strategic collaborations and growing datasets position Predictmedix for further expansion and innovation in the evolving healthcare AI ecosystem as it enters 2026.

Predictmedix AI Completes Final Tranche of Private Placement

Predictmedix AI Inc. announced the successful closing of the final tranche of its non-brokered private placement, raising a total of $612,650. The company strategically selected participants who align with its long-term vision, focusing on maintaining share-structure integrity and avoiding unnecessary dilution. This disciplined approach aims to advance their initiatives across key markets with clarity and momentum.

Predictmedix AI Secures $460,150 in First Tranche of Private Placement

Predictmedix AI Inc. announced the successful closing of the first tranche of its non-brokered private placement, raising $460,150 through the issuance of 9,203,000 units. This financing round, which includes significant insider participation, underscores strong internal confidence in the company’s growth and innovation. The funds raised are part of Predictmedix’s strategic efforts to expand its shareholder base and engage with global investors, following its participation in major European investment conferences and roadshows.